Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
Portfolio Pulse from
Mesoblast Limited has received FDA approval for Ryoncil®, the first mesenchymal stromal cell (MSC) therapy in the U.S., specifically for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in children.
December 19, 2024 | 12:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mesoblast Limited's Ryoncil® has been approved by the FDA as the first MSC therapy in the U.S., marking a significant milestone for the company and potentially boosting its market position.
The FDA approval of Ryoncil® as the first MSC therapy in the U.S. is a significant achievement for Mesoblast, likely to enhance its market position and investor confidence. This approval opens up a new market for the company, potentially increasing its revenue and stock value.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100